Nanjing Daily, March 27, 2024
(Correspondent Zhang Haiyang reporter Zhang Xi) On March 25, Angke Immune innovative macromolecular drug research and development center was unveiled in Jiangning High-tech Zone, which not only marks the development of Nanjing Angke Immune Biomedical Co., Ltd. into the fast lane, but also marks the development of macromolecular innovative drug industry in Jiangning into a new stage.
According to reports, Aoke Immune Group is composed of six companies in China, the United States and Australia, mainly focusing on the development of innovative immunotherapy drugs for malignant tumors and inflammatory diseases. One of its scientists, Professor Liu Yang, is an internationally renowned immunologist and a fellow of the American Association for the Advancement of Science. With the rapid rise of innovative drugs in China, Liu Yang and his partners established Guangzhou Aoke ImmunoBiotechnology Co., Ltd. in China in 2018, and signed a contract with Jiangning High-tech Zone in March 2022, making Nanjing its research and development center and future industrialization base in China. As of March 2024, the Nanjing Research and Development Center has invested about 280 million yuan, three research and development projects have entered the clinical stage, and the revenue of technology transfer and technical services has exceeded 14 million US dollars.
In the research and development Center of Angke Immune Innovative macromolecular drugs unveiled on the same day, the research and development laboratory, pilot workshop, quality control laboratory and so on have been renovated, and R&D personnel have been stationed and started the project experiment. Liu Yang revealed that a number of new drugs are accelerating, and in July and October 2022, the company has submitted clinical application data for the project AI-071 (a Class 1 innovative drug for the treatment of inflammatory diseases) to the Center for Drug Evaluation (CDE) of the State Food and Drug Administration and the US FDA, respectively. Complete the dosing and visit of all participants in the Australian Phase I clinical trial by the end of November 2022, and submit the latest clinical study data to the CDE in December 2022. Another combination AI-061 (for Oncology) has been filled and will begin Phase I clinical trials in Australia in March 2023. In addition, the ONC-782 project for the treatment of tumors has also submitted a patent application to the State Intellectual Property Office in November 2022. In December 2023, ONC-392, a new generation of CTLA-4 monoclonal antibody innovative drug, has been carried out phase III clinical trials in China and the United States.
On the same day, the company's "Antibody coupled drug innovation center" was launched simultaneously, and antibody coupled drug is a new type of cancer treatment drug, which belongs to the combination of chemotherapy and immunotherapy, and is the current hot track for the layout of global pharmaceutical companies.
The person in charge of Jiangning High-tech Zone said that at present, Jiangning High-tech Zone has gathered more than 300 biomedical enterprises, forming five industrial sectors of pharmaceutical research and development and production, cell therapy, research and development service outsourcing (CRO), testing and inspection, and high-end medical devices, forming a full life cycle innovation ecology covering registration testing, product certification, technical improvement, and quality system. The park will open up a green channel, set up specialized service classes and arrange service specialists to help Anco Immune build a global brand of innovative drugs and accelerate the cultivation of new quality medical productivity.
